Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player



Quick Overview

  Our aim is to reach out to the globe with in shortest possible time frame. 

To promote this objective, not only we distribute and market our cardiovascular  range of products globally through our distribution channels but we also undertake ‘contract manufacturing’& ‘formulation development ’of our wide range of generic products such as  Etalize-S 20 which contains  simvastatin USP… 20 mg & ezetimibe…10 mg.

This Etalize S 20 contains same active ingredients as VYTORIN from MERCK & CO., INC. 



Double click on above image to view full picture

Zoom Out
Zoom In


Each film coated tablet contains:

Simvastatin USP… 20 mg

Ezetimibe….. 10 mg

Excipients     Q.S.

Colour: Titanium Dioxide


ETALIZE-S (ezetimibe and simvastatin) contains ezetimibe, a selective inhibitor of intestinal cholesterol and related phytosterol absorption, and simvastatin, a HMG-CoA reductase inhibitor.

Mechanisms of action:

Ezetimibe 10 & Simvastatin 10, 20, 40 & 80 mg ezetimibe inhibits the intestinal absorption whereas simvastatin inhibits the synthesis of cholesterol.

ETALIZE-S is a combination of Ezetimibe & Simvastatin that is used for treating high levels of cholesterol in the blood. ETALIZE-S reduces total cholesterol and low densil lipoprotein cholesterol while it increases high density lipoprotein cholesterol. The ezetimibe component of ETALIZE-S lowers blood cholesterol by blocking the absorption of cholesterol, including dietary cholesterol, from the intestine. It does not affect the absorption of triglycerides. The simvastatin component of ETALIZE-S belongs to a class of drugs called HMG-CoA reductase inhibitors, commonly called "statins." Statins reduce cholesterol by blocking an enzyme in the liver (HMG-CoA reductase) that produces cholesterol. Statins lower total and LDL cholesterol in the blood as well as triglycerides. They also increase HDL cholesterol.


Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.

Primary Hyperlipidemia

ETALIZE-S (ezetimibe and simvastatin) is indicated for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and non-high-density lipoprotein cholesterol (non-HDL-C), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia.

Homozygous Familial Hypercholesterolemia (HoFH)

ETALIZE-S (ezetimibe and simvastatin) is indicated for the reduction of elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable.

Side Effects

The most commonly reported adverse reactions:

Increased ALT, Myalgia, Increased AST, Back pain, headache, upper respiratory tract infection and diarrhea.


Many of the patients who have developed rhabdomyolysis on therapy with simvastatin have had complicated medical histories, including renal insufficiency usually as a consequence of long-standing diabetes mellitus. Such patients taking ETALIZE-S (ezetimibe and simvastatin) merit closer monitoring. Therapy with ETALIZE-S (ezetimibe and simvastatin) should be temporarily stopped a few days prior to elective major surgery and when any major medical or surgical condition supervenes.


Store at temperature not exceeding 300 C.

Keep out of reach of children.

Packing :

3 x 10 Tablets in Blister Packs.